A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes

TYPE OF SARCOMA: Refractory Liposarcoma, Osteogenic Sarcoma, Ewing/Ewing-like Sarcomas, Rhabdomyosarcoma, Mesenchymal Chondrosarcoma
DRUG: Regorafenib
ACCRUAL STATUS: Recruiting

OVERALL STUDY PRINCIPAL INVESTIGATOR:
Robert Maki, MD, PhD
Professor of Medicine
Abramson Cancer Center
University of Pennsylvania School of Medicine

CLINICALTRIALS.GOV IDENTIFIER: NCT02048371

FOR STUDY DETAILS AND ELIGIBILITY CRITERIA: CLINICALTRIALS.GOV

To learn more about this study or to contact the study research staff: